Yu Chieh Su | Cancer Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Yu Chieh Su | Cancer Biology | Best Researcher Award 

Director, Division of Hematology and Oncology | E-DA Hospital | Taiwan

Dr. Yu-Chieh Su’s research focuses on molecular and translational oncology, emphasizing the mechanisms of liver cancer, head and neck cancer, leukemia, and lymphoma. His work investigates tumor biology, resistance pathways, and biomarker discovery to enhance diagnostic accuracy and therapeutic precision. He integrates molecular profiling with immuno-oncology to design targeted therapies that improve patient outcomes. A leader in applying big-data analytics and electronic medical records to oncology, Dr. Su develops predictive models and personalized treatment frameworks using genomic and clinical data integration. His multidisciplinary research extends into artificial intelligence–driven cancer prognosis, genetic biomarker validation, and the study of metabolic influences such as obesity on cancer progression. Through his leadership in national and institutional research initiatives, he has strengthened Taiwan’s position in precision oncology and data-guided cancer care. His contributions have been widely recognized, as reflected in his impressive research metrics, including 4558 total citations, an h-index of 39, and an i10-index of 102 (Google Scholar), with 3,297 citations, an h-index of162, and an i31-index of 69 (Scopus). These achievements demonstrate Dr. Su’s enduring impact on cancer biology, translational research, and the advancement of evidence-based oncology worldwide.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Su, Y.-C., et al. Prognostic significance of neutrophil-to-lymphocyte ratio in hepatocellular carcinoma. Frontiers in Oncology. — Cited by 128 articles.

Su, Y.-C., et al. Integrative genomic analysis reveals biomarkers for head and neck cancer. BMC Cancer. — Cited by 94 articles.

Su, Y.-C., et al. Clinical outcomes of hematologic malignancies under novel immunotherapy protocols. Medicine (Baltimore). — Cited by 87 articles.

Liu Yang | oncology | Best Researcher Award

Published on by Molecular Biologist

Prof Dr. Liu Yang | oncology | Best Researcher Award 

professor, The Affiliated Cancer Hospital of Nanjing Medical University, China.

Yang Liu is a Chief Physician and Associate Professor specializing in colorectal surgery. With expertise in minimally invasive and robotic surgeries, he performs over 150 advanced procedures annually. His contributions to medical research and patient care make him a key figure in the field of colorectal cancer treatment.

Profile

Scopus

Education

Yang Liu has undergone rigorous medical training, culminating in his position as a Chief Physician. He is an accomplished researcher and associate professor, continuously contributing to the development of colorectal cancer treatments.

Experience

Yang Liu is known for his extensive experience in colorectal surgery, with a focus on complex minimally invasive and robotic procedures. His surgical expertise, combined with his research on cancer genomics, has solidified his reputation in both clinical practice and academic settings.

Research Interests

Yang Liu’s research primarily focuses on the role of non-coding RNA (ncRNA) in colorectal cancer progression and metastasis. He is involved in various projects exploring epigenetic mechanisms and targeted therapies for colorectal cancer. His goal is to advance the understanding and treatment of this complex disease.

Awards

  • 2021: 2nd Prize for New Medical Technology in Jiangsu for epigenetic fusion research in colorectal cancer
  • 2019: 2nd Prize for the study of LINC00152 in colorectal cancer

Publications

  1. Multi-Dimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
  2. LUCAT1 inhibits ferroptosis in bladder cancer by regulating STAT3 mRNA stability
  3. Silver nanoparticles induce apoptosis and non-canonical autophagy in HT-29 colon cancer cells
  4. Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer

Conclusion

Yang Liu stands out as a strong candidate for the Best Researcher Award due to his significant clinical expertise, impactful research contributions, and innovation in medical technology. His leadership in colorectal surgery and mentorship roles, combined with a growing portfolio of high-impact publications and patents, underscore his potential for making groundbreaking advances in cancer treatment. To further enhance his candidacy, he could focus on increasing his international presence and broadening his research scope. Nonetheless, his accomplishments to date make him a highly competitive candidate for the award.